Navigation Links
Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
Date:10/3/2007

stekinumab would represent a much needed addition in the treatment armamentarium."

About the PHOENIX 2 Trial

The Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis Followed by Long-term Extension 2 (PHOENIX 2) trial involved 1,230 patients with chronic plaque psoriasis. Patients were randomized to receive subcutaneously administered ustekinumab or placebo. Patients randomized to receive ustekinumab received 45 mg or 90 mg doses at weeks 0 and 4 followed by the same dose every 12 weeks. Patients in the placebo group crossed over to receive either 45 mg or 90 mg doses of ustekinumab at weeks 12 and 16 and every subsequent 12 weeks. The primary end point of the study was the proportion of patients who achieved PASI 75 at week 12.

Through week 12, the placebo-controlled portion of the study, the percentages of study participants who experienced at least one adverse event (AE) were comparable between the placebo group (49 percent) and the ustekinumab 45 mg group (53 percent) and 90 mg group (48 percent). Discontinuation due to an AE occurred in 0.2 percent and one percent of patients in the respective ustekinumab groups, compared with two percent of patients in the placebo group. Two percent and one percent of patients receiving 45 mg or 90 mg ustekinumab, respectively, experienced at least one serious AE compared with two percent of patients receiving placebo.

About Psoriasis

Psoriasis is a chronic, immune-mediated disease that results from inflammation in the skin and overproduction of skin cells that accumulate on the surface causing red, scaly plaques that may itch and bleed. This chronic inflammation is driven in part by IL-12 and IL-23, cytokines involved in the regulation of the body's immune response. It is estimated that 125 million people worldwide have psoriasis, including two percent of
'/>"/>

SOURCE Centocor, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
5. Antisense Pharma: Promising Phase IIb Results of Targeted Therapy with AP 12009 in Recurrent Anaplastic Astrocytoma
6. Promising Data on Cognitive Effects of Safinamide in Early Parkinsons Disease
7. Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
11. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty ... disease and overall health is pleased to provide you with ... outlook for 2015 from the CEO, Mr. Eugene Bortoluzzi ... like to take this opportunity to share with you the ...
(Date:1/22/2015)... SAN DIEGO , Jan. 22, 2015  Profil Institute ... focused on diabetes and obesity, announced today a new ... Drug Development,  published by Springer, a leading global scientific ... extensively analyze and illustrate techniques for use in early ...
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/x3hp3g/microbiology ) ... Testing/Clinical Microbiology Market by Product, Clinical Application & ... report to their offering. Clinical microbiology ... the detection of infectious diseases. The respiratory diseases ...
Breaking Medicine Technology:Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3Global Microbiology Testing/Clinical Microbiology (Instrument, Analyzer, Incubator, Kit, Microscope, Molecular Diagnostics) Market - Forecast to 2019 2Global Microbiology Testing/Clinical Microbiology (Instrument, Analyzer, Incubator, Kit, Microscope, Molecular Diagnostics) Market - Forecast to 2019 3
... The Pharmaceutical,Research and Manufacturers of America (PhRMA) ... pipeline for major diseases affecting African,Americans to Mississippi ... pharmaceutical research companies are now testing 691 new,medicines ... or diseases that are among the top 10 ...
... 49th annual meeting recombinant factor, VIIa-albumin fusion protein ... treatment option for hemophilia patients with ... the,results of a pre-clinical study that show for the first ... human albumin, prolonging the,half- life of this therapeutic protein while ...
Cached Medicine Technology:New Report Offers Hope for Closing Health Gap for African Americans, With Nearly 700 Medicines in Pipeline 2New Report Offers Hope for Closing Health Gap for African Americans, With Nearly 700 Medicines in Pipeline 3CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity 2CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity 3
(Date:1/22/2015)... VogueQueen is a seasoned and trusted leader who consistently delivers ... to have it lead the wedding dress industry into the ... dresses for the global market. , “The CEO of VogueQueen ... focuses on continuing the goal of operational excellence and giving ...
(Date:1/22/2015)... is a famous wedding dress company offering many trendy designs. ... Facebook, Twitter, and Pinterest. The fans will have an opportunity ... every week. , Moreover, the company has extended its 2015 ... homepage for more information. , Angelweddingdress is a ...
(Date:1/22/2015)... the premier women’s dress supplier, has recently released its ... of AngelWeddingDress.com to find more details. , Many ... a bridal party. AngelWeddingDress offers a variety of gorgeous ... wedding dresses are specially designed for 2015. , AngelWeddingDress ...
(Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and David ... Show to bestow a Juvent Sports Achievement award upon ... McKitrick. The award commemorated and congratulated McKitrick for her ... won her first amateur tournament in 1979 and most ...
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo and ... federal multidistrict litigation underway in U.S. District Court, District ... Order dated January 20th, the Court has remanded a ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4
... , , , ... Living, Inc. (OTC Bulletin Board: TCSR), which develops, manages and owns ... agreement with Deutsche Bank Berkshire Mortgage, Inc. for the development of ... Trinity Heights , an 82-unit, $10 ...
... , , WILTON, Conn., July ... BlogHer Conference 2009 held Friday, July 24 and Saturday, July 25 ... about the importance of incidental sun exposure and give them a ... Aging Simulator. This year marked Eucerin,s first appearance at the ...
... , ANN ARBOR, Mich., July 28 ... the vendor for the Treatment Cost Calculator, an application that ... healthcare services. The Treatment Cost Calculator also shows consumers how ... , Clear Choice is headquartered in Bend, Oregon, ...
... , , , ... July 28 Uptown Mt. Lebanon is the place to be Saturday, August ... ULTRAparty , Mt. Lebanon,s premiere summer street party event, from ... provides an opportunity for the young (and young-at-heart!) to literally party ...
... , , , ... The State of Louisiana and Together Rx Access announced today ... help thousands of eligible uninsured Louisianans access immediate and meaningful savings ... , , The collaboration will use existing ...
... ISLANDIA, N.Y., July 28 CA, Inc. (Nasdaq: ... integrated infrastructure and performance management solution to ... The CA solution will help Seattle Children,s achieve the benefits of ... and automated fault isolation and root cause analysis for the infrastructure ...
Cached Medicine News:Health News:TrinityCare Senior Living Announces Funding Agreement for Fifth Senior Living Facility 2Health News:TrinityCare Senior Living Announces Funding Agreement for Fifth Senior Living Facility 3Health News:TrinityCare Senior Living Announces Funding Agreement for Fifth Senior Living Facility 4Health News:Eucerin Provides BlogHer Attendees With a Glimpse Into Their Skin's Future With Proprietary 'Time Machine' Aging Simulator 2Health News:Clear Choice Health Plans Selects Thomson Reuters to Deliver Healthcare Cost Information to Members - and Exceed State Transparency Requirements 2Health News:Clear Choice Health Plans Selects Thomson Reuters to Deliver Healthcare Cost Information to Members - and Exceed State Transparency Requirements 3Health News:Mt. Lebanon Comes Alive Saturday, August 8th with ULTRAparty 2Health News:The State of Louisiana and Together Rx Access Join Forces to Improve Prescription Access for Uninsured Residents 2Health News:The State of Louisiana and Together Rx Access Join Forces to Improve Prescription Access for Uninsured Residents 3Health News:The State of Louisiana and Together Rx Access Join Forces to Improve Prescription Access for Uninsured Residents 4Health News:Seattle Children's Hospital Deploys CA's Integrated Infrastructure and Performance Management Solution 2Health News:Seattle Children's Hospital Deploys CA's Integrated Infrastructure and Performance Management Solution 3
Inquire...
Protects skin from corrosive drainage with the standard wear, FlexWear skin barrier. Extra Security with porous tape....
... over extended wearing time from ... is the barrier of choice ... and confidence assured with internal ... valve that allows regulation of ...
Inquire...
Medicine Products: